Related Experiment Videos
Current pharmacotherapy for inflammatory bowel disease
1Division of Gastroenterology, University Hospital, Queen's Medical Centre, Nottingham, NG7 2UH, UK. brian.mckaig@nottingham.ac.uk
Expert Opinion on Pharmacotherapy
|March 16, 2001
Summary
Inflammatory bowel disease (IBD) treatments are evolving beyond traditional therapies. Research is advancing molecular understanding to develop targeted therapies for ulcerative colitis (UC) and Crohn
Area of Science:
- Gastroenterology and Immunology
- Pharmacology and Therapeutics
Background:
- Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), presents chronic, relapsing enteropathy with unknown causes.
- Current pharmacotherapy for IBD has remained largely static for over two decades, relying on 5-aminosalicylic acid (5-ASA) preparations, corticosteroids, antibiotics, and immunosuppressants.
Purpose of the Study:
- To review current IBD therapies and recent impactful studies.
- To examine the risks and benefits of novel agents currently in clinical trials for IBD.
Main Methods:
- Literature evaluation of existing IBD therapeutic strategies.
- Analysis of recent clinical trials and molecular understanding of IBD aetiopathogenesis.
- Assessment of novel, targeted drug therapies for IBD.
Main Results:
- Early IBD trials faced methodological challenges and patient selection difficulties due to disease heterogeneity.
- Improved research methodology has enhanced molecular understanding of IBD.
- Development of specific mediator-directed or 'designer' drug therapies for IBD is emerging.
Conclusions:
- Evidence-based approaches are being established for IBD management through well-designed clinical trials.
- Optimizing current therapies and evaluating novel agents are key future directions.
- Advances in molecular understanding are driving the development of targeted IBD therapies.